Radiopharmaceutical compositions of radioactive halogenated benzylguanidine
The present disclosure concerns radiopharmaceutical compositions of radioactive halogenated benzylguanidine (such as radioiodinated MIBG) or a pharmaceutically acceptable salt, hydrate, or solvate thereof. In a preferred embodiment, the composition has at least 97% of radiochemical purity for at least 4 days. Advantageously, the compositions of the present disclosure may be devoid of parabens, which are carcinogenic and yet are used in known radioactive MIBG compositions. The present disclosure also provides processes of preparing a radioactive halogenated benzylguanidine composition. The compositions of the present disclosure can be used in diagnosis and treatment of various diseases.
1. A radiopharmaceutical composition comprising
131 I-benzylguanidine or a pharmaceutically acceptable salt, hydrate or solvate thereof; and,
radioprotectants comprising benzyl alcohol and niacinamide,
wherein the benzyl alcohol and niacinamide are present in a ratio of about 1:0.8 to 1:32 wherein the composition has a pH of 5±0.1,
wherein the radioactivity concentration of the composition is about 20 mCi/mL to about 1 Ci/mL,
wherein the composition has a radiochemical purity of at least 99% at the time immediately following its preparation from its constituent ingredients, and,
wherein the composition has a radiochemical purity of at least 97% following four days of storage at 5±3° C. after its preparation from its constituent ingredients.
2. The radiopharmaceutical composition of claim 1 , wherein the composition does not include a paraben.
3. The radiopharmaceutical composition of claim 1 , wherein the benzyl alcohol and niacinamide are present in the composition in a ratio of from 1:1 to 1:5.
4. The radiopharmaceutical composition of claim 3 , wherein the benzyl alcohol and niacinamide are present in the composition in a ratio of from 1:1 to 1:3.
5. The radiopharmaceutical composition of claim 4 , wherein the benzyl alcohol and niacinamide are present in the composition in a ratio of about 1:1.
6. The radiopharmaceutical composition of claim 1 , wherein the benzyl alcohol and niacinamide are present in the composition in a ratio of about 1:1.8.
7. The radiopharmaceutical composition of claim 1 , wherein the benzyl alcohol is present in a concentration from 0.9% (v/v) to 2.0% (v/v).
8. The radiopharmaceutical composition of claim 1 , further comprising a buffer comprising sodium acetate and sodium chloride.
9. The radiopharmaceutical composition of claim 1 , wherein the composition is prepared by a method comprising the steps of:
(i) combining benzyl alcohol with water to form a combination;
(ii) adding niacinamide to the combination of step (i), and mixing;
(iii) adjusting the pH of the combination to 5±0.1; and
(iv) adding 131 I-benzylguanidine to the pH-adjusted combination of step (iii);
and wherein the method does not include the addition of paraben.
10. The radiopharmaceutical composition of claim 9 , wherein step (ii) of the method further comprises the addition of sodium acetate and sodium chloride.
11. The radiopharmaceutical composition of claim 1 , wherein the composition is a lyophilized powder, solution, suspension or emulsion.
12. The radiopharmaceutical composition of claim 1 , wherein the composition is provided in a container selected from the group consisting of a vial, an ampoule, a prefilled syringe, and a capsule.
13. A method for the detection or localization in a subject of primary or metastatic pheochromocytoma, neuroblastoma, paraganglioma, neuroendocrine tumor of gastroenteropancreatic tract, medullary thyroid carcinoma, or a disease resulting from myocardial ischemia and cardiomyopathy, the method comprising
administering to the subject the radiopharmaceutical composition according to claim 1 , and,
performing scintigraphic imaging in order to detect or localize the primary or metastatic pheochromocytoma, neuroblastoma, paraganglioma, neuroendocrine tumor of gastroenteropancreatic tract, medullary thyroid carcinoma, or a disease resulting from myocardial ischemia and cardiomyopathy in the subject.
14. A method for diagnosing or treating in a subject pheochromocytoma, neuroblastoma, paraganglioma, neuroendocrine tumor of the gastroenteropancreatic tract, medullary thyroid carcinoma, or a disease resulting from myocardial ischemia and cardiomyopathy the method comprising
administering to the subject the radiopharmaceutical composition according to claim 1 ; and,
when diagnosis is required, performing scintigraphic imaging in order to diagnose the primary or metastatic pheochromocytoma, neuroblastoma, paraganglioma, neuroendocrine tumor of gastroenteropancreatic tract, medullary thyroid carcinoma, or a disease resulting from myocardial ischemia and cardiomyopathy in the subject.
15. The radiopharmaceutical composition according to claim 1 , wherein the radioprotectants consist of benzyl alcohol and niacinamide.
16. The radiopharmaceutical composition according to claim 1 , wherein the radioprotectants do not include gentisic acid.